Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM 4: Belantamab Mafodotin + Pembrolizumab in RRMM
NCT03848845Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2019
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by GSK. Started Mar 2019; status: completed.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03848845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848845.